13 Nov AHA23: Successful Early Trial of Stem Cells Used To Re-Muscle Heart in Advanced Heart Failure
MedicalResearch.com Interview with:
Dr. Zimmermann
Prof. Dr. Wolfram-Hubertus Zimmermann
Director, Institute of Pharmacology and Toxicology
University Medical Center Göttingen
Georg-August University
Göttingen, Germany
MedicalResearch.com: What is the background for this study?
Response: Involvement in research and development in the field of tissue engineered heart repair since 25+ years.
Bench-to-bed translation of our research.
MedicalResearch.com: How are the stem cell obtained?
Response: We make use of induced pluripotent stem cells as starting material to obtain heart muscle cells for the engineering of Engineered Human Myocardium (EHM) and its use as Biological Ventricular Assist Tissue (BioVAT).
MedicalResearch.com: What are the main findings?
Response: Endpoint of Phase I (dose finding) met with the identification of a safe maximal dose (SMD). Clinical proof-of-principle for remuscularization of the failing heart in patients with advanced heart failure obtained with first evidence for improved function and symptoms in patients treated with the SMD.
MedicalResearch.com: What should readers take away from your report?
Response: Sustainable remuscularization of the failing heart with tissue engineered myocardium is possible in patients with advanced heart failure under guideline-directed optimal medical care.
MedicalResearch.com: What recommendations do you have for future research as a results of this study?
Response: Continuation into Phase II with SMD for proof-of-concept. Further work on cardiomyocyte-based myocardial repair is warranted.
MedicalResearch.com: Is there anything else you would like to add? Any disclosures?
Response: This is an IIT (sponsor: University Medical Center Göttingen) supported by the German Center for Cardiovascular Research (DZHK), a German-government supported center committed to facilitate bench-to-bed translation, and Repairon GmbH, a start-up which aims at translating our research findings into clinical use.
COI: Wolfram Zimmermann is founder and shareholder of Repairon GmbH
Citation: AHA 2023 abstract
Wolfram H Zimmermann, UNIVERSITY MED CTR GOETTINGEN, Goettingen, Germany; Anas Aboud, Univ Medical Ctr Schleswig-Holstein, Campus Lübeck, Lübeck, Germany; Felix Bremmer, UNIVERSITY MED CTR GOETTINGEN, Goettingen, Germany; Ingo Eitel, Univ Heart Ctr Luebeck, Luebeck, Germany; Stephan Ensminger, Univ Medical Ctr Schleswig-Holstein, Campus Lübeck, Lübeck, Germany; Tim Friede, Univ Medical Ctr Göttingen, Goettingen, Germany; Buntaro Fujita, Univ Medical Ctr Schleswig-Holstein, Campus Lübeck, Lübeck, Germany; Gerd P Hasenfuss, Univ Medical Ctr Göttingen, Gottingen, Germany; Kristian Hellenkamp, Univ Medical Ctr Göttingen, Goettingen, Germany; Christoph Herrmann-Lingen, UNIVERSITY MED CTR GOETTINGEN, Goettingen, Germany; Ahmad-fawad Jebran, UNIVERSITY HOSPITAL GOETTINGEN, Goettingen, Germany; Johannes Kowallick, Univ Medical Ctr Göttingen, Goettingen, Germany; Ingo Kutschka, Univ Medical Ctr Göttingen, Göttingen, Germany; Tobias Legler, UNIVERSITY MED CTR GOETTINGEN, Goettingen, Germany; Joachim Lotz, UMG Goettingen, Goettingen, Germany; Christina Paitazoglou, Univ Medical Ctr Schleswig-Holstein, Campus Lübeck, Lübeck, Germany; Marius Placzek, Univ Medical Ctr Göttingen, Goettingen, Germany; Joachim Riggert, Monika Sadlonova, UNIVERSITY MED CTR GOETTINGEN, Goettingen, Germany; Tim Seidler, Univ Medical Ctr Göttingen, Göttingen, Germany; Malte Tiburcy, UNIVERSITY MEDICAL CENTER, Goettingen, Germany
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition.
Some links may be sponsored. Products are not endorsed.
Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on November 13, 2023 by Marie Benz